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Background: Fluralaner is a novel systemic ectoparasiticide for dogs providing long-acting flea- and tick-control
after a single oral dose. This study investigated the safety of oral administration of fluralaner at 3 times the highest
expected clinical dose to Multi Drug Resistance Protein 1 (MDR1(−/−)) gene defect Collies.
Methods: Sixteen Collies homozygous for the MDR1 deletion mutation were included in the study. Eight Collies
received fluralaner chewable tablets once at a dose of 168 mg/kg; eight sham dosed Collies served as controls. All
Collies were clinically observed until 28 days following treatment.
Results: No adverse events were observed subsequent to fluralaner treatment of MDR1(−/−) Collies at three times
the highest expected clinical dose.
Conclusions: Fluralaner chewable tablets are well tolerated in MDR1(−/−) Collies following oral administration.
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Fluralaner is a novel systemically administered insecticidal
and acaricidal product that provides long acting efficacy
after oral administration to dogs. Fluralaner belongs to a
new class of compounds, the isoxazolines. These com-
pounds have activity against γ-aminobutyric acid- (GABA-)
and glutamate-gated chloride channels with significant
selectivity for insect neurons over mammalian neurons
[1]. A field study has shown that a single fluralaner
dose administered orally to dogs provides at least
twelve weeks of flea- and tick-control [2]. The long
duration of activity offers a more convenient treatment
over monthly flea and tick control treatments with a
potential compliance advantage, reducing the risk of
vector-transmitted diseases.
This systemic treatment will likely be administered to
dogs carrying a deletion mutation of the Multi-Drug Resist-
ance gene (MDR1). Dogs homozygous for this mutation do
not express functional P-glycoprotein [3], a drug efflux
pump highly expressed at the blood–brain barrier that re-
stricts drug accumulation in the central nervous system
through an efflux-based transport mechanism [4]. MDR1* Correspondence: feli.walther@msd.de
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as rough- and smooth-coated Collie, Shetland Sheepdog,
Australian Shepherd, McNab, Longhaired Whippet, Silken
Windhound, Old English Sheepdog, English Shepherd,
Border Collie and Wäller [5,6]. Homozygous mutations
(MDR1(−/−)) are associated with an increased risk of
neurotoxicity for multiple drugs, leading to clinical findings
such as depression, mydriasis, salivation, tremor, ataxia and
coma [3,7-10]. Although MDR1(−/−) dogs do not express a
functional P-glycoprotein, inter-individual variability in
sensitivity is reported [7,11]. In addition to the low
in vitro affinity of fluralaner to mammalian neuronal
receptors [1], fluralaner did not cause any signs of
neurotoxicity in a previous high-dose safety study in
healthy dogs [12] nor in a field study [2]; this study
was designed to confirm the safety of oral fluralaner
administration in dogs with proven MDR1(−/−) muta-
tion. To account for variability in susceptibility, flura-
laner was administered at overdoses, i.e. 3 times the
highest expected clinical dose of 56 mg/kg BW [2].Methods
This single-center, randomized, parallel-group and
investigator-blinded study included sixteen healthy
male and female rough-coated Collies, 1.7 - 4.0 yearsl Ltd. This is an Open Access article distributed under the terms of the Creative
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22 kg). Dogs were from four different litters, with three
different litters per study group. All Collies were homozy-
gous for the MDR1 deletion mutation, as confirmed by
gene testing (www.vetmed.wsu.edu/VCPL).
This study was conducted in Michigan, USA, in com-
pliance with the Animal Welfare Act as overseen by the
United States Department of Agriculture (USDA) and
ethical approval was obtained before the start of the
study. Study was approved by the Institutional Animal
Care and Use Committee (IACUC no. CHK-13-0419).
Healthy Collies, based on initial physical and clinical
pathological evaluation, were housed individually and
fed a standard commercial diet at recommended rates.
Collies were randomly allocated to study groups using
the following block randomization procedure: dogs were
separated by gender and ranked in ascending order of
body weight; if two dogs had identical bodyweights, they
were sub-ranked by increasing microchip number. The
top two dogs within each gender formed a block that
was randomly allocated between each of the two
study groups, and the process repeated until 4 male
and 4 female dogs were allocated to each study group.
A total of 8 Collies received fluralaner and 8 sham
dosed Collies served as controls.
The expected dose range for fluralaner administration
during routine clinical use is between 25 and 56 mg/kg
[2]. This study evaluated the single oral administration
of fluralaner in a chewable tablet at 3 times the highest
expected clinical dose (168 mg fluralaner/kg body weight).
The individual dose for each treated dog was based on the
body weight determined one day before treatment. The tab-







































Figure 1 Mean fluralaner plasma concentration (± standard deviation) fintended to be marketed as Bravecto™, produced under
Good Manufacturing Practice (GMP). Homogeneous distri-
bution of fluralaner in tablets was previously confirmed as
part of the product development. Whole fluralaner tablets
(1400 mg fluralaner/tablet) and tablet portions were admin-
istered to each dog to deliver the calculated dose. The ad-
ministration of cut tablets resulted in a maximum deviation
from the target dose of 0.5 mg fluralaner/kg body weight.
Following tablet administration, a small amount of water
was administered to encourage swallowing. Control dogs
remained untreated and were sham dosed with water only.
On the treatment day (day 0), dogs of both groups were fed
a portion of canned diet within 30 minutes prior to treat-
ment and another portion of canned diet directly after treat-
ment (approximately 350 grams in total). Dogs were fed
around the time of treatment to ensure high systemic flura-
laner exposure, since fluralaner bioavailability is higher in
fed dogs [13]. The normal daily ration of food was offered
one hour following treatment.
All dogs were observed by a technician for general
health before treatment and during the first hour follow-
ing fluralaner administration. Clinical assessments were
performed by a veterinarian, who was masked to the
treatment status of each dog, at 3, 6, 9, 12, 18, 24, 30,
36, 42, 48, 54, 60 and 72 hours after administration.
Assessments focused on, but were not limited to: be-
haviour, salivation, vomiting, ataxia, muscular tremor,
mydriasis and pupillary reflex. Between 3 and 7 days
after treatment dogs were observed four times daily
and then twice daily for the remaining 21 days of the
study period by a technician masked to the treatment
status of each dog. Additional physical examinations
were performed by a veterinarian (masked to the treatment14 21 28
(days)
r tablet 168 mg/kg
ollowing oral administration at 168 mg/kg to MDR1(−/−) Collies.
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and 28. The veterinary study director assessed all parame-
ters recorded and all clinical findings for their relationship
to fluralaner treatment. Any treatment-related findings
were classified as adverse events. Blood samples were col-
lected at intervals over the study period to monitor sys-
temic exposure to fluralaner. Blood sampling time points
were selected based on previous pharmacokinetic data [14]
and blood samples were analyzed using a validated LC-
MS/MS method (lower limit of quantification = 10 ng/ml).Results and discussion
All fluralaner-treated dogs rapidly consumed the complete
portion of food offered prior to and directly after flurala-
ner administration.
Fluralaner was quantifiable in plasma of treated dogs
from the first post-treatment sampling time point through-
out the study, confirming dose-related systemic exposure
(Figure 1).
No vomiting, excessive salivation or any other findings
were observed during the first hour of clinical observa-
tion following treatment or during the frequent clinical
assessments performed over the 3 days following flurala-
ner administration. Clinical findings observed over the
study period included an abraded callus on the medial
hock of one dog pre-treatment, a dog who bit its tongue
during feeding pre-treatment, evidence of estrus in three
dogs of the fluralaner group and an observation of
tachycardia in a control-group dog. These clinical find-
ings were minor and not related to fluralaner treatment.
This clinical safety evaluation of fluralaner, a novel sys-
temic antiparasitic drug, in MDR1(−/−) dogs treated or-
ally at 3 times the highest recommended clinical dose
did not detect any adverse events. The detailed clinical
observations were timed to provide maximum coverage
during the period of highest expected systemic fluralaner
concentrations to assure that potential neurological clin-
ical signs would have become apparent. However, no
signs of neurotoxicity, or any other adverse events, were
observed during these frequent observations.
These results are consistent with a previous safety study
[12] in healthy Beagle dogs, that found no evidence of
neurotoxic symptoms or any other treatment-related find-
ings associated with repeated oral administration of up to
280 mg fluralaner/kg.Conclusions
Fluralaner chewable tablets are well tolerated in MDR1
(−/−) Collies following oral administration.Competing interests
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